INTERSOLAR EUROPE 2022: FOCUS ON INTELLIGENT DUAL USE OF AREAS
22.4.2022 10:39:00 EEST | Business Wire | Press release
At the Intersolar Europe exhibition, established and new players in the energy sector exchange information about new developments and trends, experience innovations and exploit business potential. The focus of the world’s leading exhibition for the solar industry is, among other things, the dual use of areas in agriculture, on bodies of water and in buildings. Intersolar Europe will be held at Messe München from May 11 to 13.
Photovoltaic (PV) production is booming in Germany and throughout Europe: almost 26 gigawatts (GW) of PV installations were connected to the grid in the EU in 2021 – a record growth of 34%. As in the previous year, Germany was the largest PV market in the EU with an addition of 5.3 GW. The European inter-trade organization, SolarPower Europe, expects installed solar power capacity to double to more than 326 GW by 2025.
At Intersolar Europe 2022, companies will present innovations and products developed for the world of new energies. Some examples include Agri-photovoltaics and Floating PV. The efficient dual use of areas for agriculture and solar power generation is developing dynamically: in 2020, plants for the generation of more than 14 GW had already been installed worldwide, according to the Fraunhofer Institute for Solar Energy Systems (ISE). Floating PV is now considered the third pillar of the global solar market. An estimated 400 plants with a total capacity of more than 3 GW are already in operation in over 40 countries. At Intersolar Europe 2022, these rapid developments will be prominent, with a large number of exhibitors presenting innovative products and solutions from the Agri-PV and Floating PV sectors.
Building-integrated PV (BIPV) is another key topic at Intersolar Europe 2022. With a view to the German market, this is where the greatest potential can be found for reducing the CO2 footprint of buildings, using space efficiently and strengthening sustainable development.
Intersolar Europe forms part of The smarter E Europe. From May 11 to 13, 2022, it will present cross-industry and cross-sector solutions for the energy transition and security of supply in Europe at Messe München. 1,450 exhibitors will showcase products, solutions and business models across 132,000 square meters in twelve exhibition halls.
Topics such as Agri-PV, Floating PV and BIPV will also be addressed at the Intersolar Europe Conference on May 10 and 11, 2022 at the International Congress Center Munich (ICM). Participants will learn all about the markets, technologies and financing of PV projects. One area under the spotlight will be large-scale PV power plants and systems, especially with regard to Agri-PV and floating PV. On May 10 at 6 p.m., innovators and experts will be honored with the Intersolar AWARD at the ICM (Hall 1).
https://www.intersolar.de/home?lang=en
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005509/en/
Contact information
Solar Promotion GmbH | PO Box 100 170 | 75101 Pforzheim
Horst Dufner | +49 7231 58598-0
info@intersolar.de
Press-contact:
fischerAppelt, relations | Otl-Aicher-Str. 64 | 80807 Munich
Felizia Rein | +49 89 74 74 66 40
felizia.rein@fischerappelt.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
